Short and Long-Term Mortality Trends for Cancer Patients with Septic Shock Stratified by Cancer Type from 2009 to 2017: A Population-Based Cohort Study

Kim, Youn-Jung; Kim, Min-Ju; Kim, Ye‐Jee; Kim, Won Young

doi:10.3390/cancers13040657

Cited by 16 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported the mortality trends of septic shock in cancer patients with claims data using diagnostic codes [ 16 ]. We used a clinical surveillance definition of septic shock based on concurrent vasopressors, antibiotics, and blood cultures.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Impact of Neutropenia in Cancer Patients with Septic Shock: A 2009–2017 Nationwide Cohort Study

Kim

2022

Cancers

Self Cite

View full text Add to dashboard Cite

(1) Background: Neutropenia’s prognostic impact on mortality in cancer patients with septic shock remains controversial despite recent advances in cancer and sepsis management. This population-based, case–control study aimed to determine whether neutropenia could be related to an increase in short-term and long-term mortality. (2) Methods: This population-based, case–control study used data from the National Health Insurance Service of Korea. Adult cancer patients who presented to the emergency department with septic shock from 2009 to 2017 were included. The 30-day and 1-year mortality rates were evaluated as short-term and long-term outcomes. Cox proportional hazard regression was performed after adjusting for age, sex, Charlson comorbidity index, and neutropenia. (3) Results: In 43,466 adult cancer patients with septic shock, the 30-day and 1-year mortality rates were 52.1% and 81.3%, respectively. In total, 6391 patients had neutropenic septic shock, and the prevalent cancer type was lung cancer, followed by leukemia, non-Hodgkin’s lymphoma, stomach cancer, and colon cancer. Furthermore, 30-day and 1-year mortality was lower in patients with neutropenia than in those without neutropenia. After adjustment for confounders, neutropenia was independently associated with decreased 30-day and 1-year mortality rates. (4) Conclusions: In cancer patients presenting to the emergency department with septic shock, the presence of neutropenia did not increase mortality. This suggests that neutropenia may not be used as a single triage criterion for withholding intensive care in cancer patients presenting to the emergency department with septic shock.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Impact of Neutropenia in Cancer Patients with Septic Shock: A 2009–2017 Nationwide Cohort Study

Kim

2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…So, what is the mortality rate for cancer patients in septic shock? To assess short- and long-term mortality trends in septic shock patients with cancer by cancer type, Kim et al examined adult cancer patients presenting to the emergency department with septic shock from 2009 to 2017, and found that among the 43,466 adult cancer patients with septic shock (90% solid and 10% hematologic cancer cases), the 30-day and 1-year mortality rates were 52.1% and 81.3%, respectively ( 9 ). The 30-day mortality rate is basically consistent with the results of our study.…”

Section: Discussionmentioning

confidence: 99%

“…In a previous study, Dimopoulos et al found that a history of stage I or II solid tumors was an independent risk factor for 28-day mortality in sepsis ( 8 ). Further, Kim et al showed that the 30-day and 1-year mortality rates were 52.1% and 81.3% in adult sepsis shock patients with cancer ( 9 ). There is also a lack of relevant research on the effect of dobutamine on septic shock patients with tumor.…”

Section: Introductionmentioning

confidence: 99%

Early administration of dobutamine in the treatment of septic shock patients with tumor-a retrospective comparative cohort study

Wu¹,

Yin²,

Tang³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background Studies have found that dobutamine may be beneficial to protect organs function in patients with septic shock, but there is still a lack of relevant research in septic shock patients with tumor. The study sought to explore the role of the early administration of dobutamine in the treatment of septic shock patients with tumors. Methods We retrospectively collected the data of tumor patients who developed septic shock at Sun Yat-sen University Cancer Center between June 2008 and November 2021. All the patients were divided into the following 3 groups: (I) the early administration group (<3 days, n=15); (II) the late administration group (≥3 days, n=22); and (III) the non-administration group (n=85). The primary observation indicator was 28-day mortality, and the secondary observation indicators included the shock reversal rate, the length of stay in the intensive care unit (ICU) and the duration of mechanical ventilation. There was no statistical difference in the basic data of the three groups. Results The early administration group had a significant decrease in 28-day mortality compared to the late and non-administration groups (log-rank P=0.018). The comparison between the groups showed that the 28-day mortality of the early administration group was significantly lower than that of the non-administration group [20.0% vs. 58.8%, P=0.013, hazard ratios (HRs) =0.248, 95% confidence intervals (CIs): 0.077–0.796]. There was no statistically significant difference in 28-day mortality between the late administration group and the non-administration group (63.6% vs. 58.8%, P=0.682, HR =0.983, 95% CI: 0.543–1.778). Additionally, the early administration group had a significantly increased shock reversal rate (P=0.014), shortened length of stay in the ICU (P<0.001), and reduced duration of mechanical ventilation (P=0.049). Conclusions Early use of dobutamine may be beneficial to reduce the in-hospital mortality of septic shock patients with tumor, but the sample size of this study was small, which still needs to be confirmed by a multi-center randomized controlled clinical study.

show abstract

“…Chronic kidney disease was defined by the presence of diagnostic codes (N03, N05, N165, N18‐9, N250, I12‐3, Z490‐2, Z940, Z992, E102, E112, E132, E142, or T861) 20 . Malignancy was defined as the presence of diagnostic codes (C00–C97) with cancer specific deductible code (V027, V193‐4) from the Health Insurance Review and Assessment Service 21 . The accuracy of the diagnosis algorithm with ICD‐10 codes for comorbidities is 85.0%–94.1% 10,22,23 …”

Section: Methodsmentioning

confidence: 99%

“…20 Malignancy was defined as the presence of diagnostic codes (C00-C97) with cancer specific deductible code (V027, V193-4) from the Health Insurance Review and Assessment Service. 21 The accuracy of the diagnosis algorithm with ICD-10 codes for comorbidities is 85.0%-94.1%. 10,22,23…”

Section: Covariatesmentioning

confidence: 99%

Associations of heart failure with susceptibility and severe complications of COVID‐19: A nationwide cohort study

Kim

Park

Smıth

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

Infection is associated with occurrence and worsening of heart failure (HF). However, studies on the association of susceptibility and severe complications of coronavirus disease 2019 (COVID-19) with HF history are limited. From the Korean nationwide COVID-19 data set, 212,678 participants with at least one severe acute respiratory syndrome coronavirus 2 real-time reverse transcription polymerase chain reaction (RT-PCR) test were included between January 1 and June 4, 2020. To investigate the association of HF with susceptibility and severe complications of COVID-19, 1:4 ratio propensity score matching (PSM) and logistic regression analysis were performed. The primary outcome was a composite outcome of mechanical ventilation, intensive care unit (ICU) admission, and death. After PSM, COVID-19 PCR positivity did not show a significant difference according to HF history in multivariable analysis (odds ratio [OR]: 0.91, 95% confidence interval (CI) (0.79-1.04), p = 0.146). Of 7630 individuals with confirmed COVID-19 infection, 310 (4.1%) had HF history. The overall primary outcome occurred in 426 (5.6%) individuals, including 159 (2.1%) cases of mechanical ventilation, 254 (3.3%) cases of ICU admission, and 215 (2.8%) cases of death. In multivariate logistic analysis, presence of HF history was associated independently with primary outcome (OR: 1.99, 95% CI: 1.42-2.79, p < 0.001), particularly mortality (OR: 2.02, 95% CI: 1.36-3.00, p < 0.001). Our study demonstrated that HF history is associated poor prognosis, particularly mortality, in COVID-19. Patients with HF can have severe complication if infected with COVID-19; therefore, careful management are necessary.

show abstract

Short and Long-Term Mortality Trends for Cancer Patients with Septic Shock Stratified by Cancer Type from 2009 to 2017: A Population-Based Cohort Study

Cited by 16 publications

References 36 publications

Prognostic Impact of Neutropenia in Cancer Patients with Septic Shock: A 2009–2017 Nationwide Cohort Study

Prognostic Impact of Neutropenia in Cancer Patients with Septic Shock: A 2009–2017 Nationwide Cohort Study

Early administration of dobutamine in the treatment of septic shock patients with tumor-a retrospective comparative cohort study

Associations of heart failure with susceptibility and severe complications of COVID‐19: A nationwide cohort study

Contact Info

Product

Resources

About